Literature DB >> 9119623

Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb.

B Jönsson1, M C Weinstein.   

Abstract

Data relevant to economic evaluation are being collected alongside clinical trials with increasing frequency. When these trials involve health outcomes and resource utilization in many different countries, numerous methodologic problems arise. This paper describes and discusses the methodology for economic evaluation that will be used in the Economic Substudy of GUSTO IIb, as an example of how to address the problems that arise in economic evaluations linked to international trials.

Mesh:

Substances:

Year:  1997        PMID: 9119623     DOI: 10.1017/s0266462300010229

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  8 in total

Review 1.  Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors:  Francis Pang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Clinical trials in orthopaedics research. Part III. Overcoming operational challenges in the design and conduct of randomized clinical trials in orthopaedic surgery.

Authors:  Elena Losina; James Wright; Jeffrey N Katz
Journal:  J Bone Joint Surg Am       Date:  2012-03-21       Impact factor: 5.284

3.  Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.

Authors:  Gunnar Johansson; Emma B Andreasson; Per E Larsson; Claus F Vogelmeier
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference?

Authors:  R Goeree; A Gafni; M Hannah; T Myhr; G Blackhouse
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

5.  Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.

Authors:  N O Stålhammar; J Carlsson; R Peacock; S Müller-Lissner; M A Bigard; G B Porro; J Ponce; J Hosie; M Scott; D G Weir; C Fulton; K Gillon; K D Bardhan
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 6.  OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis.

Authors:  E Losina; J Ranstam; J E Collins; T J Schnitzer; J N Katz
Journal:  Osteoarthritis Cartilage       Date:  2015-05       Impact factor: 6.576

7.  Bayesian modelling of healthcare resource use in multinational randomized clinical trials.

Authors:  Aline Gauthier; Andrea Manca; Susan Anton
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.

Authors:  Helen A Dakin; Sarah Wordsworth; Chris A Rogers; Giselle Abangma; James Raftery; Simon P Harding; Andrew J Lotery; Susan M Downes; Usha Chakravarthy; Barnaby C Reeves
Journal:  BMJ Open       Date:  2014-07-29       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.